AU2019404552A1 - Amorphous sparsentan compositions - Google Patents

Amorphous sparsentan compositions Download PDF

Info

Publication number
AU2019404552A1
AU2019404552A1 AU2019404552A AU2019404552A AU2019404552A1 AU 2019404552 A1 AU2019404552 A1 AU 2019404552A1 AU 2019404552 A AU2019404552 A AU 2019404552A AU 2019404552 A AU2019404552 A AU 2019404552A AU 2019404552 A1 AU2019404552 A1 AU 2019404552A1
Authority
AU
Australia
Prior art keywords
compound
pharmaceutical composition
amorphous
pharmaceutically acceptable
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019404552A
Other languages
English (en)
Inventor
James Francis HULVAT
Dainius Macikenas
Kale Ruby
Xiangming Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Travere Therapeutics Inc
Original Assignee
Travere Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Travere Therapeutics Inc filed Critical Travere Therapeutics Inc
Publication of AU2019404552A1 publication Critical patent/AU2019404552A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019404552A 2018-12-21 2019-12-20 Amorphous sparsentan compositions Abandoned AU2019404552A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862783947P 2018-12-21 2018-12-21
US62/783,947 2018-12-21
PCT/US2019/068094 WO2020132594A1 (en) 2018-12-21 2019-12-20 Amorphous sparsentan compositions

Publications (1)

Publication Number Publication Date
AU2019404552A1 true AU2019404552A1 (en) 2021-07-15

Family

ID=69187971

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019404552A Abandoned AU2019404552A1 (en) 2018-12-21 2019-12-20 Amorphous sparsentan compositions

Country Status (12)

Country Link
US (1) US20220048900A1 (cg-RX-API-DMAC7.html)
EP (1) EP3897834A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022514569A (cg-RX-API-DMAC7.html)
KR (1) KR20210125994A (cg-RX-API-DMAC7.html)
CN (1) CN114126712A (cg-RX-API-DMAC7.html)
AU (1) AU2019404552A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021012226A2 (cg-RX-API-DMAC7.html)
CA (1) CA3124127A1 (cg-RX-API-DMAC7.html)
IL (1) IL284186A (cg-RX-API-DMAC7.html)
MA (1) MA54542A (cg-RX-API-DMAC7.html)
MX (1) MX2021007258A (cg-RX-API-DMAC7.html)
WO (1) WO2020132594A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7524167B2 (ja) 2018-10-04 2024-07-29 トラビア セラピューティクス, インコーポレイテッド Iv型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物
WO2022266370A1 (en) 2021-06-17 2022-12-22 Aria Pharmaceuticals, Inc. Sparsentan for treating idiopathic pulmonary fibrosis
WO2023127853A1 (ja) * 2021-12-28 2023-07-06 株式会社アークメディスン 化合物、アンジオテンシンiiタイプ1受容体拮抗剤及び医薬組成物
JP2025183466A (ja) * 2022-11-11 2025-12-17 株式会社アークメディスン 化合物、エンドセリンa受容体拮抗剤、アンジオテンシンiiタイプ1受容体拮抗剤及び医薬組成物
JP2026508235A (ja) * 2023-02-24 2026-03-10 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 芳香環含有誘導体アンタゴニストの塩、その製造方法及び応用
CN118666826A (zh) * 2024-08-23 2024-09-20 成都臻拓医药科技有限公司 一种司帕生坦原料药的重结晶纯化方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
WO2001044239A2 (en) * 1999-12-15 2001-06-21 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
WO2010114801A1 (en) * 2009-03-31 2010-10-07 Ligand Pharmaceuticals Inc. Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy
WO2010135350A2 (en) * 2009-05-20 2010-11-25 Pharmacopeia, Llc Biphenyl intermediate compounds and methods for the preparation of a dual angiotensin ii and endothelin a receptor antagonist
JP2019530713A (ja) 2016-10-13 2019-10-24 レトロフィン, インコーポレイテッド 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物

Also Published As

Publication number Publication date
CN114126712A (zh) 2022-03-01
MX2021007258A (es) 2021-08-16
JP2022514569A (ja) 2022-02-14
IL284186A (en) 2021-08-31
CA3124127A1 (en) 2020-06-25
MA54542A (fr) 2021-10-27
WO2020132594A1 (en) 2020-06-25
US20220048900A1 (en) 2022-02-17
KR20210125994A (ko) 2021-10-19
BR112021012226A2 (pt) 2021-09-08
EP3897834A1 (en) 2021-10-27

Similar Documents

Publication Publication Date Title
US20220048900A1 (en) Amorphous sparsentan compositions
US20250325522A1 (en) Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders
JP7409696B2 (ja) キナーゼ阻害剤の塩およびその組成物
US20090191265A1 (en) Capsule Formulation of Pirfenidone and Pharmaceutically Acceptable Excipients
WO2022246200A1 (en) Methods of treating kidney diseases or disorders
KR102301743B1 (ko) 에피나코나졸 경구용 조성물
JP2001511450A (ja) チアガビンを含有する制御放出性の医薬組成物
WO2024073672A1 (en) Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders
US20100008956A1 (en) Composition and combinations of carboxylic acid losartan in dosage forms
WO2025064688A1 (en) Sparsentan for treating immunoglobulin a nephropathy (igan)
US20210052608A1 (en) Methods of treating bacterial infections with minocycline
WO2022264004A1 (en) Pharmaceutical composition comprising itraconazole
US20220175774A1 (en) Bioavailable Oral Dosage Form Of Tyrosine-Kinase Inhibitor
BR122025008185A2 (pt) Usos terapêuticos de compostos de bifenil sulfonamida para a fabricação de um medicamento para tratar doenças ou transtornos renais em um indivíduo
HK1168758A (en) Capsule formulation of pirfenidone and pharmaceutically acceptable excipients

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period